The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility

Although there is evidence to support progesterone luteal-phase support in assisted reproductive technology, the role of progesterone and other steroids outside of the assisted reproductive technology setting is less well defined, and reviewed in this article.
Published
Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Like

Volume 106, Issue 7, Pages 1600-1607

Authors:

Alexander M. Quaas, M.D., Ph.D., Karl R. Hansen, M.D., Ph.D.

Abstract:

Fertility treatment strategies are evolving, with a more rapid transition to assisted reproductive technology (ART) treatments after unsuccessful non-ART treatments. This trend increases the potential importance of adjuvant treatments in non-ART cycles, such as steroid hormone supplementation. It has been established that success rates of ART treatments are increased with the use of luteal support with progesterone. In the setting of non-ART cycles, however, the evidence is less clear, and clinical practices vary widely between providers and clinics. In this review, we aimed to provide an overview of the current evidence for the use of steroid hormone supplementation, including progesterone for luteal support, estrogens, androgens, and mineralocorticoids, in the setting of non-ART treatments for ovulatory women.


Read the full text here.


Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Recommended Content